

Remarks

Claims 19 and 20 are currently pending in the application. Claims 19 and 20 have been amended to correct inadvertent errors. Support for the definitions of R5, R6, R7 and R8 may be found in the originally filed specification on page 4, line 24 – page 5, line 18 and on page 10, line 27 – page 11, line 21.

§112 Rejections

I. Claims 19 and 20 were rejected under 35 USC§112, second paragraph as being indefinite.

Examiner correctly points out several inadvertent errors in Claims 19 and 20. Clearly, C₁ alkenyl and alkynyl cannot exist nor can C₁-C₂ cycloalkyl, cycloalkenyl or cycloalkynyl. Applicants have also deleted the reference to C₃-C₈ cycloalkynyl since C₃-C₇ cycloalkynyl would be too strained to be isolated. Applicant respectfully submits that the correction of these inadvertent errors *via* the amendments to Claims 19 and 20 renders the rejection moot.

Applicant respectfully submits that Claims 19 and 20 are both allowable and request a timely notice of allowance.

Respectfully Submitted:

Date:

October 18, 2005



Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871